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Background: Collagen IV-related nephropathies, including thin basement membrane nephropathy and Alport
Syndrome (AS), are caused by defects in the genes COL4A3, COL4A4 and COL4A5. Diagnosis of these conditions can
be hindered by variable penetrance and the presence of non-specific clinical or pathological features.
Methods: Three families with unexplained inherited kidney disease were recruited from Shanghai, China. Whole
exome sequencing (WES) was performed in the index case from each family and co-segregation of candidate
pathogenic mutations was tested by Sanger sequencing.
Results: We identified COL4A4 missense variants [c.G2636A (p.Gly879Glu) and c.C4715T (p.Pro1572Leu)] in the
21-year-old male proband from family 1, who had been diagnosed with mesangial proliferative nephropathy at age
14. COL4A4 c.G2636A, a novel variant, co-segregated with renal disease among maternal relatives. COL4A4 c.C4715T
has previously been associated with autosomal recessive AS and was inherited from his clinically unaffected father.
In family 2, a novel COL4A3 missense mutation c.G2290A (p.Gly997Glu) was identified in a 45-year-old male
diagnosed with focal segmental glomerulosclerosis and was present in all his affected family members, who
exhibited disease ranging from isolated microscopic hematuria to end stage renal disease (ESRD). In family 3, ESRD
occurred in both male and females who were found to harbor a known AS-causing COL4A5 donor splice site
mutation (c.687 + 1G > A). None of these variants were detected among 100 healthy Chinese individuals.
Conclusion: WES identified 2 novel and 2 known pathogenic COL4A3/COL4A4/COL4A5 mutations in 3 families with
previously unexplained inherited kidney disease. These findings highlight the clinical range of collagen IV-related
nephropathies and resolved diagnostic confusion arising from atypical or incomplete clinical/histological findings,
allowing appropriate counselling and treatment advice to be given.
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The type IV collagen α3α4α5 chain is a major compo-
nent of the glomerular basement membrane (GBM) and
is a heterotrimer that is encoded by three genes: COL4A3,
COL4A4 and COL4A5. While COL4A3 and COL4A4 are
located on chromosome 2, COL4A5 lies on the X chromo-
some. Mutations in any of these genes can lead to type IV* Correspondence: jianggeng-ru@hotmail.com; d.gale@ucl.ac.uk
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unless otherwise stated.collagen-related nephropathy in which there is disruption
of the normal glomerular basement membrane architec-
ture and kidney disease [1]. In general, heterozygous mu-
tations result in mild disease characterized by focal or
diffuse thinning of the GBM, with or without isolated mi-
croscopic hematuria (MH) and termed thin basement
membrane nephropathy (TBMN). In a minority (esti-
mated at 10-20%) of patients with TBMN and heterozy-
gous mutation of COL4A3, 4 or 5 there is progressive
renal dysfunction with end stage renal disease (ESRD)
in later life, usually after the fifth decade [2]. Males he-
mizygous for a COL4A5 mutation, and individuals of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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COL4A3/4 mutations, are at risk of X-linked and auto-
somal recessive Alport Syndrome (AS) respectively, in
which there is a high likely of ESRD within the first
three decades of life, associated with sensorineural deaf-
ness and ocular abnormalities, including asymptomatic
dot and fleck retinopathy and lenticonus.
Genetic testing is the gold standard in diagnosing col-
lagen IV-related nephropathies. In AS (a rare disease
with 1:5000 prevalence), X-linked (XL) inheritance is re-
ported in 80-85% of patients autosomal recessive AS
(ARAS) accounts for 15% of cases. TBMN reported to
affect at least 1% of the worldwide population is fre-
quently associated with heterozygous mutations of
COL4A3, COL4A4 or COL4A5. Although more than
1000 mutations (nearly 300 in COL4A3 and COL4A4,
and 756 in COL4A5) have been identified in AS and
TBMN [3], the challenges in the diagnosis of collagen
IV nephropathies remain. The large size of COL4A3,
COL4A4 and COL4A5 genes, comprising 48–53 exons
each, and the lack of mutational hot spots make individ-
ual screening of multiple genes by Sanger sequencing
difficult and expensive. While historically a COL4A5
mutation has been identified in 90% of XLAS [4], in sus-
pected autosomal disease the detection rate of detection
of COL4A3/COL4A4 mutations has been reported as
low as 20% [5]. The clinical and light microscopic (LM)
kidney biopsy findings of some collagen IV-related ne-
phropathy patients are difficult to distinguish from other
conditions such as focal segmental glomerulosclerosis
(FSGS) and glomerulonephritis, which may lead to in-
correct diagnosis [6]. In families presenting with isolated
microscopic hematuria only, kidney biopsy may not be
clinically indicated and genetic testing is frequently not
performed, presumably owing to the cost.
Recent availability of next-generation sequencing (NGS)
technologies including whole exome sequencing (WES)
make it possible to simultaneously test thousands of
genes in an unbiased, high-throughput and cost-efficient
manner. WES has recently corrected the diagnosis of
AS patients mistaken for familial focal segmental glo-
merulosclerosis (FSGS) [7,8]. Targeted exome capture of
COL4A3/COL4A4/COL4A5 followed by NGS has also
been used clinically to screen clinically suspected AS
patients [9,10]. In this study using WES, we identified
novel and rare type IV collagen gene mutations in 3 un-
related Chinese families with glomerulonephritis and no
extra-renal involvement, in whom diagnosis had been
difficult to make because of atypical clinical presenta-
tion and complex or incomplete histological findings.
Since affected members of all 3 families had progressed
to ESRD, precise molecular diagnosis was clinically valu-
able because it allowed genetic counseling and predict-
ive testing to be offered to relatives, aided therapeuticdecision-making and allowed more accurate prognostic
advice to be given.Methods
Human patients
The study was conducted according to protocols ap-
proved by the Ethical Committee of Shanghai Xin Hua
Hospital (No. XHEC-D-2014-002), and written informed
consent was obtained from each participant. DNA was
extracted from blood samples using QIAamp DNA midi
kit (Qiagen). DNAs from 100 ethnically matched Chinese
healthy individuals were used as controls.Whole exome sequencing (WES) analysis
Targeted exome capture was performed using genomic
DNA from each subject using SureSelect Human All
Exon Target Enrichment System (Agilent). Paired-end se-
quencing (76 bp) was performed using the Genome
Analyzer IIx (Illumina Inc). Read alignment to the human
genome assembly hg19 using the novoalign alignment tool
(Novocraft Technologies). Variant calling and annotations
were obtained using the Samtools mpileup utility [11] and
Annovar tools [12] respectively.
To identify pathogenic variants, a stepwise filtering
process was used that firstly removed non-coding, syn-
onymous and common variants (minor allele frequency,
MAF >0.005 in the 1000 genome project database or
our in-house database of >800 exomes). The remaining
non-synonymous coding and splice-site variants were
further filtered to include those occurring in a set of 32
genes (Additional file 1: Table S1) known to be associ-
ated with non-syndromic familial nephropathy and/or
kidney disease with phenotypes compatible with those in
the 3 families. The 32 genes were selected after search in
databases including PubMed, the Online Mendelian In-
heritance in Man (OMIM) and the Human Gene Muta-
tion Database (HGMD). Mapping, coverage and filtering
statistics are summarized in Additional file 2: Table S2
and Additional file 3: Table S3.
Multiple protein sequence alignment to assess evolu-
tionary conservation of residues was performed using
UCSC Genome Browser (genome.ucsc.edu).Confirmation of candidate variants using Sanger
sequencing
Candidate variants identified by WES were validated by
Sanger sequencing using an ABI PRISM 3730xl Genetic
Analyzer (Applied Biosytems). Primers sequences are
available upon request. Co-segregation of candidate var-
iants was tested in all family members for whom DNA
was available and co-segregating candidate variants were
genotyped in 100 unrelated Chinese healthy controls.
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Clinical description of the 3 families and whole exome
sequencing results
Family 1
The index case (III-1) was a 21 year-old male who pre-
sented with microscopic hematuria (MH) and protein-
uria (1.0 g/24 hrs) at age 14 (Figure 1A). Renal biopsy at
that time was inconclusive: LM showed mesangial prolif-
erative nephropathy (MsPGN) (Figure 1B) with segmental
afferent arteriolar C3 deposition (1+) on immunofluores-
cence (IF). EM revealed early segmental obliteration in
one capillary loop and mesangial cell proliferation with no
apparent GBM abnormalities. After treatment with angio-
tensin converting enzyme inhibitor (ACEi) and oral corti-
costeroids, proteinuria decreased to 300-500 mg/24 hrs
but MH persisted, and renal function remained normal.
His grandmother (I-2) had undergone a kidney biopsy at
age 55 and this was reported as showing typical LM and
IF findings of IgA nephropathy. She had been treated with
oral corticosteroids for 5 years but progressed to ESRD
8 years later. III-1’s mother (II-2) also developed MH and
proteinuria in her 30s but declined renal biopsy.
We performed WES in individual III-1 and this identified
two heterozygous candidate COL4A4 missense mutations,
c.G2636A (p.Gly879Glu) and c.C4715T (p.Pro1572Leu).Figure 1 COL4A4 mutations identified in Family 1. (A) Pedigree for fam
hematuria and proteinuria but with normal renal function are indicated wit
in gray. Asterisk indicates the individual examined by whole exome sequen
hematoxylin and eosin showing segmental mesangial cell proliferation (X4
heterozygous missense COL4A4 c.G2636A (p.Gly879Glu) and c.C4715T (p.Pro
showing conservation of the mutated Gly879 and Pro1572 residues.Sanger sequencing (Figure 1C) confirmed the presence of
the COL4A4 c.G2636A in II-2 and I-2 and revealed that
the COL4A4 c.C4715T was inherited from III-1’s father
(II-3) who is well, with normal urinalysis and blood
pressure. The novel COL4A4 c.G2636A mutation pre-
dicts a glycine to glutamine substitution in a collage-
nous domain of the protein. Further Sanger sequencing
confirmed this mutation not present in 100 healthy
ethnicity-matched controls. COL4A4 c.C4715T muta-
tion predicts a proline to leucine substitution in the
non-collagenous (NC1) domain of the protein. Unlike col-
lagenous domain glycine substitutions, COL4A4 point
mutations resulting in a substitution of proline for another
amino acid are rarely associated with disease: of the 15
unique COL4A4 missense mutations involving proline
that are present in the LOVD database (//grenada.lumc.
nl/LOVD2/COL4A/), only this and one other, p.Pro1132-
Leu, are considered to be likely pathogenic [13]. However,
several pathogenic proline substitutions have been re-
ported in COL4A5 (e.g. p.Pro628Leu [14]; p.Pro739Ser
[15]; p.Pro1523Thr [16]; p.Pro1590Leu [17]), establishing
that this type of mutation, occurring in either collagenous
or non-collagenous domains of the protein can disrupt
Type IV collagen. Since the COL4A4 p.Pro1572Leu muta-
tion lies in the non-collagenous domain at a residue thatily 1. A full-shaded icon denotes ESRD; individuals with microscopic
h a half-shaded icon; individual with unknown phenotype is indicated
cing. (B) Light microscopic renal biopsy from III-1, stained with
0). (C) Sanger sequencing electropherograms confirming the
1572Leu) mutations, and multiple species protein sequence alignment







Pathogenic variants Zygosity Novel or
clinical
SIFTa PolyPhen2b Mutation at
conserved position
1 III-1 MsPGN
COL4A4 c.G2636A (p.Gly879Glu) Het Novel 0.001 1.0 Yes
COL4A4 c.C4715T (p. Pro1572Leu) Het Clinical [18,19] 0 1.0 Yes
2 II-4 FSGS COL4A3 c.G2290A (p.Gly997Glu) Het Novel 0 1.0 Yes
3 II-2 Biopsy not performed COL4A5 (c.687 + 1G > A) Het Clinical [20] N/A N/A Yes
aA SIFT score of <0.05 is predicted to be deleterious.
bA Polyphen2 score is predicted to be “probably damaging” if it is >0.85, “possibly damaging” if between 0.85 and 0.2, and “benign” if < 0.2.
MsPGN, mesangial proliferative nephropathy; FSGS, focal segmental glomerulosclerosis; N/A, not available.
Figure 2 Reprocessed electron micrographs of the renal biopsy
from patient III-1 of family 1. Capillary loop showing segmental
thinning of GBM (arrow) with no irregular GBM thickening and
lamellation (X 4000).
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chains and has previously been described in two separate
ARAS cases [18,19], we believe there is a high likelihood it
is a pathogenic variant. Using PolyPhen 2 (genetics.bwh.
harvard.edu/pph2/) and SIFT (sift.jcvi.org) to predict
possible functional effects, both COL4A4 c.G2636A
(p.Gly879Glu) and c.C4715T (p.Pro1572Leu) were clas-
sified as pathogenic and are highly conserved across
multiple organisms (results summarized in Table 1).
Given the unexpected compound heterozygous COL4A4
mutations identified in III-1, we reprocessed and reana-
lyzed his EM specimen. Only segmental thinning of GBM
was found with no irregular GBM thickening and lamella-
tion (Figure 2), consistent with a Type IV collagen-related
disorder, but not diagnostic of recessive AS. Subsequent
visual and hearing examinations were normal. His grand-
mother’s (I-2) renal biopsy, performed >15 years ago was
unavailable for review. The presence of two in trans mu-
tations in III-1 may explain why he has developed pro-
teinuria early and suggests an increased risk of renal
impairment developing at younger age in him compared
with his heterozygous relatives.
Family 2
The index patient (II-4) from Family 2 was a 45-year-old
Chinese male with over 10 years’ history of proteinuria
(2-3 g/24 hr), MH, hypertension and recurrent gout at-
tacks. Renal biopsy was performed at age 39 with the
diagnosis of FSGS on LM. EM was not performed be-
cause of sample insufficiency. He was treated with corti-
costeroids for 2 years but progressed to stage 4 chronic
kidney disease (GFR = 25 ml/min by age 45). His mother
(I-2) had 20 years’ history of proteinuria and MH and
progressed to ESRD aged 55. Sisters (II-2 and II-3) of
the index patient both exhibited MH and proteinuria
(0.5-1.5 g/24 hr) with preserved renal function, and II-
4’s niece (III-1) was found to have isolated MH during
her pregnancy. None of the affected family members re-
ported hearing or visual impairment.
WES was performed on II-4. This identified a novel
heterozygous COL4A3 missense mutation [c.G2290A
(p.Gly997Glu)] and a rare heterozygous FN1 missensemutation [c.A1448G (p.Glu483Arg)] with MAF of 0.0005.
No non-synonymous rare variants were identified in genes
associated with inherited FSGS. Sanger sequencing con-
firmed the cosegregation of COL4A3 c.G2290A in all 5
affected family members but the FN1 missense mutation
[c.A1448G (p.Glu483Arg)] was not present in I-2, II-3 and
III-1 (Figure 3A). COL4A3 c.G2290A mutation predicts
substitution of a highly conserved glycine by glutamine in
the collagenous domain of the protein (Figure 3B) and
was classified as pathogenic by in silico software (Results
Figure 3 COL4A3 mutation identified in Family 2. (A) Pedigree for family 2. A full-shaded icon denotes ESRD; A 3/4-shaded icon denotes
individual with impaired renal function; a half-shaded icon denotes individuals with microscopic hematuria and proteinuria but with normal renal
function; 1/4-shaded icon denotes isolated hematuria. Asterisk indicates the individual examined by whole exome sequencing. (B) Sanger
sequencing electropherograms confirming the heterozygous missense COL4A3 c.G2290A (p.Gly997Glu) mutation, and multiple species protein
sequence alignment showing conservation of the mutated Gly997 residue.
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among 100 unrelated Chinese control individuals.
Family 3
The index patient (II-2) in kindred 3 was a 65 year-old
female who developed nephrotic syndrome at age 30,
and renal biopsy was not performed at that time. There
was no response to oral corticosteroids given for 3 months.
She progressed to ESRD at age 57. Her mother (I-2) and
one of her younger sisters (II-5) reached ESRD at ages 40
and 50 respectively, and her younger brother (II-4) re-
ceived a kidney transplant at age 32 and died 8 years later.
II-5’s son (III-2) developed heavy proteinuria and edema
at age 2 and progressed to CKD3 (GFR of 55 ml/min)
at age 30. The other sister (II-3) of the index patient
developed proteinuria with increased serum creatinine
(150 umol/L) at age 50, with no MH. Her renal func-
tion remained stable on no medical therapy over the
next 10 years. Ultrasound in II-3 showed small kidneys
with no cysts. II-3 and III-2 declined renal biopsy.
None of the affected family members reported hearing
or visual impairment.
Whole exome sequencing was performed in II-2. After
variant filtering, we identified a COL4A5 donor splice
site variant (c.687 + 1G > A), which was previously repor-
ted to cause XLAS [20], and a rare heterozygous CUBN
missense mutation [c.C9206T (p.Thr3069Ile)] with MAF
of 0.003 (Figure 4A). Sanger sequencing (Figure 4B) con-
firmed that COL4A5 (c.687 + 1G > A) cosegregated in allaffected members in this family while the CUBN variant
was not present in affected individuals II-3 and III-2,
and was present in clinically unaffected individuals II-7
and III-3 (results summarized in Table 1). Sanger se-
quencing confirmed that COL4A5 (c.687 + 1G > A) was
not present in 100 healthy Chinese controls.
Discussion
Current options for genetic testing include Sanger se-
quencing of candidate gene(s), next generation sequen-
cing of a selected panel of candidate genes, WES, and
whole genome sequencing. In the clinical setting, tar-
geted panels are gaining favor because of the relatively
modest cost and the detail with which the targeted re-
gions are analyzed which can allow reliable copy number
estimation, detecting or excluding within-gene duplica-
tions and deletions. Two recent studies using targeted
panels of COL4A3/A4/A5 for the genetic diagnosis in
patients suspected of having a Type IV collagen-related
nephropathy identified a likely pathogenic mutation in
55% and 83.2% patients tested [9,10]. A major limitation
of this approach is that if the panel used does not in-
clude the gene responsible in a patient, the mutation will
not be detected. This is a significant problem in the current
era when new genes are being implicated in Mendelian
kidney diseases each year. WES yields data on a far greater
number of genes, including those not initially considered
candidates for the phenotype being investigated. This al-
lows a diagnosis to be made where detailed phenotype data
Figure 4 Overview of the COL4A5 mutation identified in Family 3. (A) Pedigree for family 3. A full-shaded icon denotes ESRD; a 3/4-shaded
icon denotes impaired renal function; individual with unknown phenotype is indicated in gray. Asterisk indicates the individual examined by
whole exome sequencing. (B) Sanger sequencing electropherograms confirming the COL4A5 donor splice site mutation (c.687 + 1G > A), and
multiple species sequence alignment showing conserved GT in the donor splice site.
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may detect variants that predict disease unrelated to the in-
dication for testing in an individual patient, and which they
would rather not know about. These considerations must
be taken into account when consenting for and analyzing
WES data, and are of course avoided when only genes
known to be related to the trait under investigation are se-
quenced. A further advantage is that unbiased screening of
large numbers of genes may allow epistatic effects to be de-
tected, such as that of NPHS2 variant p.R229Q which, al-
though not detected in any of the patients in this study, is
known to be associated with proteinuria and renal impair-
ment in TBMN [21,22]. Whole genome sequencing is cur-
rently less widely applied outside a research setting – the
amount of sequencing, data storage and analysis required
are significantly greater than for WES and it is not clear if
the associated costs are justified when the vast majority of
detectable disease-causing variants lie within coding re-
gions that are covered by WES.
The 3 families in this study posed well-recognized
diagnostic challenges in kidney disease, including aty-
pical or late clinical presentation with unavailable or
inconclusive pathology findings: patients from family
1 and family 2 in this study were initially diagnosed
with MsPGN, IgAN and FSGS. Some individuals were
treated with extended courses of corticosteroids that
very likely had no beneficial effect on their renal dis-
ease and would not have been used had the correct
underlying diagnosis been known to the treating clin-
ician at the time.In family 1, although we identified compound hete-
rozygous COL4A4 mutations in the index patient, his
reprocessed EM findings and clinical course of disease
was more suggestive of heterozygous COL4A-related
disease than ARAS. Interestingly, the index patient’s
grandmother was initially diagnosed with IgAN and the
unexpected identification of the co-segregating COL4A4
[c.G2636A (p.Gly879Glu)] mutation in her suggested
co-existence of a collagen IV-related nephropathy. Since
she was the only family member who developed ESRD
in this family, her poor renal outcome may be attribut-
able to the coincidence of these two kidney diseases, al-
though it is well recognized that a single heterozygous
COL4A3/COL4A4 mutation is associated with late-onset
ESRD in up to 20% of patients [2]. Superimposition of
other comorbidities, such as IgAN, in collagen IV-related
nephropathy (especially in TBMN) is not rare. A previous
study has shown that 30% of familial IgAN cases had
GBM abnormalities and TBMN could be a significant
contributor to disease in these families [23].
LM findings of AS often resemble those of FSGS or
MsPGN. Data retrieved from the Alport Syndrome data-
base in South China recently showed that the misdiag-
nosis rate of AS is 13% (52 out of 398), with MsPGN
(26.9%) and FSGS (19.2%) being the most common mis-
diagnoses [24]. In family 2, WES identified no known or
likely FSGS-associated variants, but a novel heterozy-
gous COL4A3 [c.G2290A (p.Gly997Glu)] mutation that
is predicted to have a functional impact on the colla-
gen IV heterotrimer structure. This strongly suggests an
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rather than an inherited or acquired podocytopathy.
Apart from pathological heterogeneity, collagen IV-
related nephropathy is clinically heterogeneous within
and between families. In male XLAS patients, the muta-
tion location and nature predict clinical severity. Large
deletions and insertions, rearrangements, splicing and
nonsense mutations, and mutations within the NC1 do-
main of COL4A5 are associated with severe consequences
with ESRD occurred before age 20, whereas missense mu-
tations involving the collagenous domain are responsible
for a less severe type of AS [25]. In female XLAS patients,
the explanation for the wide variability in outcomes is un-
certain, as genotype-phenotype correlation has not been
observed. The largest study, of 288 female patients from
195 families, showed that 18% patients progressed to
ESRD over the course of the follow-up and only 12% of
them reached ESRD by age 40 [26]. In family 3, in which
we detected a COL4A5 donor splice site mutation (c.687 +
1G >A) known to cause XLAS, the disease was unusually
severe (for X-linked disease) in the female patients I-2, II-2
and II-5 and unusually mild in the male patient III-2. The
intrafamilial heterogeneity in female patients of family 3
may be due to variable X-chromosomal inactivation [27].
Other factors such as unknown modifying genes and envir-
onmental factors may also affect the natural history of dis-
ease in different affected family members.
Recently, the first clinical application of WES reported
that the success rate of mutation identification in pa-
tients with genetic disorder is approximately 25% [28].
In our study, sequencing one affected family member
using WES, combined with stepwise variant filtering
strategy, we identified mutations of collagen IV genes in
3 undiagnosed glomerulonephritis families with no extra-
renal involvement. This result shows that WES is a power-
ful diagnostic tool that can complement renal biopsy and
can non-invasively provide a diagnosis in patients with fa-
milial kidney disease, particularly when clinical informa-
tion is limited or non-specific.
Conclusion
WES identified 2 novel and 2 known pathogenic COL4A3/
COL4A4/COL4A5 mutations in 3 families with previously
unexplained inherited kidney disease. These findings high-
light the clinical range of collagen IV-related nephropathies
and resolved diagnostic confusion arising from atypical or
incomplete clinical/histological findings, allowing appropri-
ate counselling and treatment advice to be given.
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